Curanex Pharmaceuticals (CURX) Current Leases (2025 - 2026)
Curanex Pharmaceuticals' (CURX) quarterly Current Leases came in at $94411.0 in Q2 2026, up 33.66% on a YoY basis from $70636.0 in Q2 2025, and down 23.05% quarter-over-quarter from $122689.0 in Q4 2025.
Powered by 
Analysis
Curanex Pharmaceuticals (CURX) Current Leases (2025 - 2026) Analysis & Trends
Curanex Pharmaceuticals (CURX) has reported Current Leases for 2 consecutive years, with $94411.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Current Leases rose 33.66% year-over-year to $94411.0; the trailing twelve-month figure through Jun 2026 stood at $94411.0 (up 33.66% YoY), and the FY2025 full-year result was $122689.0, changed N/A from the prior year.
- Current Leases slipped to $94411.0 in Q2 2026 per CURX's latest filing, from $122689.0 in the prior quarter.
- Across five years, Current Leases topped out at $122689.0 in Q4 2025 and bottomed at $61150.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | - |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 274.00 Mn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 263.86 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 16.75 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 4.26 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | - |
| 10 | Curanex Pharmaceuticals | 5.97 Mn | 3.03 Mn | - | 94,411.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 94,411.00 |
| Dec 31, 2025 | 122,689.00 |
| Sep 30, 2025 | 61,150.00 |
| Jun 30, 2025 | 70,636.00 |